NCT05225584
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have at least 2 prior systemic standard of care treatments to be eligible for Part 1a and at least 1 prior systemic standard of care treatment to be eligible for Part 1b
Exclusions: Patients with a history or suspicion of central nervous system (CNS) metastases
https://ClinicalTrials.gov/show/NCT05225584